Liver transplantation candidates with hepatocellular carcinoma (HCC) have significantly lower 90-day odds of waitlist removal due to clinical deterioration or death compared to non-HCC candidates with similar Model for End-Stage Liver Disease (MELD) scores.
Extensive intratumor heterogeneity, seen in samples obtained from renal carcinomas, may lead to underestimation of the tumor genomics based on single tumor-biopsy samples.
In the United States, the use of partial nephrectomy procedures to manage renal masses in patients with renal cell carcinoma (RCC) increased significantly from 2002-2008.
The use of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) to treat cancer is associated with an increased risk of fatal adverse events (FAEs) but there is no difference in rates of FAEs between the different VEGFR TKIs or tumor types, according to a meta-analysis.
Argos Therapeutics announced results from AGS-003-006, a Phase 2 study of AGS-003 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC). The results showed a statistically significant correlation between anti-tumor memory T cell responses and overall survival.
Pfizer announced that the FDA has approved Inlyta (axitinib) for the treatment of patients with advanced renal cell carcinoma who have not responded to another drug for this type of cancer.
The American Cancer Society (ACS) Nutrition and Physical Activity Guidelines were recently updated and published in the January/February issue of CA: A Cancer Journal for Clinicians.
Pfizer announced that the FDA has accepted its filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC).
The FDA is informing the public that use of Actos (pioglitazone; Takeda) for more than one year may be associated with an increased risk of bladder cancer.
